Skip to content

The effectiveness of Problem Solving Therapy in stroke patients.

The effectiveness of Problem Solving Therapy in stroke patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21620
Enrollment
200
Registered
2010-08-30
Start date
2011-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Patients in the treatment condition will receive Problem Solving Therapy (PST), a group training for 8 weeks, in addition to standard care. The therapy teaches patients to solve problems in a systemat

Sponsors

Erasmus University Medical Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. First and only stroke; 2. Between 18 and 75 years of age; 3. Being treated in the outpatient phase of rehabilitation; 4. Able to follow a 1 hour groupsession each week; 5. Legally capable.

Exclusion criteria

Exclusion criteria: 1. Progressive neurological disorders; 2. Life expectancy less than 12 months; 3. Insufficient understanding of the Dutch language; 4. Drug or alcohol abuse; 5. Subdural haematoma.

Design outcomes

Primary

MeasureTime frame
The primary outcome measures are coping style and quality of life. These are measured using validated questionnaires at timepoints T0 (before intervention), T1 (after intervention), T2 (6 months after intervention) and T3 (12 months after intervention).

Secondary

MeasureTime frame
The secondary outcome measures are health care consumption, depression and participation. These are measured using validated questionnaires at timepoints T0 (before intervention), T1 (after intervention), T2 (6 months after intervention) and T3 (12 months after intervention). The cost-effectiveness of the intervention will be assesses as well.

Contacts

Public ContactM.M. Visser

P.O. Box 2040

m.m.visser.1@erasmusmc.nl+31 (0)10 2412412

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)